Scancell Holdings (LSE:SCLP) Net Change in Cash

: £-10.96 Mil (TTM As of Oct. 2023)

View and export this data going back to 2010. Start your Free Trial

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Scancell Holdings's Net Change in Cash for the six months ended in Oct. 2023 was £-6.84 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Oct. 2023 was £-10.96 Mil.

Scancell Holdings Net Change in Cash Historical Data

The historical data trend for Scancell Holdings's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scancell Holdings Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Net Change in Cash

Get a 7-Day Free Trial

-5.74

-0.99

37.54

-12.39

-8.81

Scancell Holdings Semi-Annual Data
	Apr14	Oct14	Apr15	Oct15	Apr16	Oct16	Apr17	Oct17	Apr18	Oct18	Apr19	Oct19	Apr20	Oct20	Apr21	Oct21	Apr22	Oct22	Apr23	Oct23
Net Change in Cash	Get a 7-Day Free Trial															-5.54	-6.85	-4.69	-4.12	-6.84

Scancell Holdings Net Change in Cash Calculation

Scancell Holdings's Net Change in Cash for the fiscal year that ended in Apr. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-8.14	+	0.081	+	-0.746	+	0
	=	-8.81

Scancell Holdings's Net Change in Cash for the quarter that ended in Oct. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -6.814 + 0.148 + -0.175 + 0

= -6.84

Net Change in Cash for the trailing twelve months (TTM) ended in Oct. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-10.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scancell Holdings Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Scancell Holdings's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Scancell Holdings (LSE:SCLP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (LSE:SCLP) » Definitions » Net Change in Cash

Comparable Companies

LSE:FUM LSE:REDX LSE:HVO LSE:OBD LSE:ARIX LSE:4BB LSE:ETX LSE:AREC LSE:SBTX LSE:DEST OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Traded in Other Exchanges

SCLP.GB:UK SCP:Germany

Address

Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD

Website

https://www.scancell.co.uk

Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (LSE:SCLP) Headlines

No Headlines